Reduction of the Endocochlear Potential by the New “Loop” Diuretic, Bumetanide

Reference

• Ahlström P., Thalmann I., Thalmann R., Ise I. Cyclic AMP and adenylate cyclase in the inner ear. Laryngoscope 1975; 85: 1341
   Google Scholar
• Asano Y., Masuzawa H., Tabata Y., et al. Clinical trial of bumetanide (cs-380). Basic Pharmacol Ther 1974; 2: 47
   Google Scholar
• Bosher S. K., Smith C., Warren R. L. The effects of ethacrynic acid upon the cochlear endolymph and the stria vascularis. A preliminary report. Acta Otolaryngol (Stockh) 1973; 75: 184
   PubMed Web of Science ®Google Scholar
• Bourke E. Frusemide, bumetanide, and ototoxicity. Lancet 1976; i: 917
   Google Scholar
• Brown R. D. Effect of bumetanide on the positive endocochlear dc potential of the cat. Tox Appl Pharmacol 1976; 38: 137
   PubMed Web of Science ®Google Scholar
• Davies D. L., Lant A. F., Millard N. R., Smith A. J., Ward J. W., Wilson G. M. Renal action, Therapeutic use, and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther 1974; 15: 141
   PubMed Web of Science ®Google Scholar
• Ebel H. Effect of diuretics on renal Na K ATPase and adenyl cyclase. Naunyn-Schmiedebergs Arch Pharmacol 1974; 281: 301
   PubMedGoogle Scholar
• Feit P. W. Aminobenzoic acid diuretics. 2'.4-sub-stituted-3-amino-5-sulfamylbenzoic acid derivatives. J Med Chem 1971; 14: 432
   PubMed Web of Science ®Google Scholar
• Honrubia V., Strelioff F., Sitko S. T. Physiological basis of cochlear transduction and sensitivity. Ann Otol Rhinol Laryngol 1976; 85: 697
   PubMed Web of Science ®Google Scholar
• Hook J. B., Williamson H. E. Addition of the saluretic action of furosemide to the saluretic action of certain other agents. J Pharmacol Exp Ther 1965; 148: 88
   PubMedGoogle Scholar
• Kim K. E., Onesti G., Moyer J. H., Swarz C. Ethacrynic acid and furosemide. Diuretic and hemodynamic effects and clinical uses. Am J Cardiol 1971; 27: 407
   PubMed Web of Science ®Google Scholar
• Kuijpers W. Cation transport and cochlear function. Thesis, University of Nijmegen. 1969
   Google Scholar
• Kuijpers W., Wilberts D. P. C. The effect of ouabain and ethacrynic acid on ATPase activities in the inner ear of the rat and guinea pig. ORL 1976; 38: 321
   Google Scholar
• Kusakari J., Thalmann R. Effects of anoxia and ethacrynic acid upon ampullar endolymphatic potential and upon high energy phosphates in ampullar wall. Laryngoscope 1976; 86: 132
   PubMed Web of Science ®Google Scholar
• Kusakari J., Ise I., Comegys T. H., Thalmann I., Thalmann R. Effect of ethacrynic acid, furosemide and ouabain upon the endolymphatic potential and upon high energy phosphates of the stria vascularis. Laryngoscope 1977, in press
   Google Scholar
• Laragh J. H. The proper use of newer diuretics. Ann Intern Med 1967; 67: 606
   Google Scholar
• Olesen K. H., Sigurd B., Steiness E., Leth A. Bumetanide, a new potent diuretic, A clinical evaluation in congestive heart failure. Acta Med Scand 1973; 193: 119
   PubMed Web of Science ®Google Scholar
• Østergaard E. H., Magnussen M. P., Nielsen C K., Eilertesen E., Frey H. H. Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamyl-benzoic acid (Bumetanide), a new potent diuretic. Arz-neim Forsch 1972; 22: 66
   PubMed Web of Science ®Google Scholar
• Paloheimo S., Thalmann R. Comments on Tissue concentrations of ethacrynic acid and inhibition of enzymes and electrophysiological responses in the cochlea. J Acoust Soc Amer 1975; 59: 708
   Google Scholar
• Pillay K. G., Schwarz F. D., Aimi K., Kark R. M. Transient and permanent deafness following treatment with ethacrynic acid in renal failure. Lancet 1969; i: 77
   Google Scholar
• Prazma J., Thomas W. G., Fischer N. D., Preslar M. J. Ototoxicity of ethacrynic acid. Arch Otolaryngol 1972; 95: 448
   PubMed Web of Science ®Google Scholar
• Quick C. A., Duvall A. J., III. Early changes in the cochlear duct from ethacrynic acid: an electro-microscopic evaluation. Laryngoscope 1970; 80: 954
   PubMed Web of Science ®Google Scholar
• Sellick P. M., Johnstone B. M. Differential effects of ouabain and ethacrynic acid on the labyrinthine potentials. Pflügers Arch 1974; 352: 339
   PubMed Web of Science ®Google Scholar
• Schneider W. J., Becker E. L. Acute transient hearing loss after ethacrynic acid therapy. Arch Intern Med 1966; 117: 715
   PubMed Web of Science ®Google Scholar
• Schwarz G. H., David D. S., Riggio R. R., Stenzel K. H., Rubin A. L. Ototoxicity induced by furosemide. N Engl J Med 1970; 282: 1413
   PubMedGoogle Scholar
• Stein J. H., Wilson C. B., Kirkendall W. M. Differences in the acute effects of furosemide and ethacrynic acid in man. J Lab Clin Med 1968; 71: 654
   PubMedGoogle Scholar
• Thalmann R., Kusakari J., Miyoshi T. Dysfunctions of energy releasing and consuming processes of the cochlea. Laryngoscope 1973; 83: 1690
   PubMed Web of Science ®Google Scholar
• Thalmann R., Ise I., Bohne B. A., Thalmann I. Actions of “loop” diuretics and mercurials upon the cochlea. Acta Otolaryngol (Stockh)SJ 1977; 221
   Google Scholar
• Tria E., Luly P., Tomasi V., Trevisani A., Barnabei. Modulation by cyclic AMP in vitro of liver plasma membrane (Na+-K+)-ATPase and protein kinases. Biochim Biophys Acta 1974; 343: 297
   PubMedGoogle Scholar